BUZZ - Bristol Myers Squibb shares rise on positive trial results for cancer and lung disease drugs

October 12 - ** Bristol-Myers Squibb (BMY.N) shares rose 3.7% in premarket trade to $61.32

** The low-dose regimen of its experimental drug (link) achieved the primary endpoint in a late-stage clinical trial among patients with idiopathic pulmonary fibrosis, a serious lung scarring disease

** The pharmaceutical company said that its drug admilparant, at a 60-milligram dose (twice daily), showed a statistically significant effect in preserving lung function compared to placebo

** In addition, its experimental radiopharmaceutical therapy (link) significantly slowed disease progression in patients with rare, advanced gastrointestinal and pancreatic tumors who had previously received treatment but whose conditions continued to worsen

** The therapy RYZ101 is one of the high-profile treatment approaches, acting like a "cannonball" by delivering radioactive particles directly to tumor tissue or tumor-associated cells to kill cancer cells

** As of the previous trading day’s close, BMY had gained 9.6% so far this year—while the S&P 500 Healthcare Index rose 10.3% over the same period .SPXHC

(To facilitate non-native English speakers, Reuters has automatically translated its reports into several other languages. As automated translation may contain errors or lack necessary context, Reuters does not guarantee the accuracy of the automated translation and provides it solely for the convenience of readers. Reuters is not liable for any damage or loss caused by the use of the automated translation feature.)